Therapy, Medicine, Controlled Substances Act, Bristol-Myers Squibb, Drug Enforcement Administration, Digital
Sumitomo clinches Myovant buyout after upping offer to $2.9B https://t.co/4FCFZIYBsw
OpenSumitomo clinches Myovant buyout after upping offer to $2.9B
A few weeks after balking at a buyout offer, Myovant Sciences appears to have successfully negotiated upward. The former Vivek Ramaswamy company accepted a deal from its majority owner Sumitomo Pharma to buy out the rest of its shares, Myovant announced Sunday night. ...
Sumitomo clinches Myovant buyout after upping offer to $2.9B https://t.co/4FCFZIYBsw
Open
Sumitomo clinches Myovant buyout after upping offer to $2.9B
A few weeks after balking at a buyout offer, Myovant Sciences appears to have successfully negotiated upward. The former Vivek Ramaswamy company accepted a deal from its majority owner ...
We are sorry, we could not find the related article
If you are curious about Biotech and Biotech & Healthcare
Please click on:
Subscribe to Biotech - Biotech & Healthcare
CD28 kills again? Mitch Gold’s plan to make cell therapy 2.0 history crashes after another patient dies of cardiogenic shock
Mitch Gold’s plans to push the envelope on cell therapy 2.0 has crashed into a fresh safety issue — and this time his biotech is ready to call it quits on the lead in-house effort. Seven ...